Detail View

Korean red ginseng polysaccharide as a potential therapeutic agent targeting tau pathology in Alzheimer's disease
Citations

WEB OF SCIENCE

Citations

SCOPUS

Metadata Downloads

Title
Korean red ginseng polysaccharide as a potential therapeutic agent targeting tau pathology in Alzheimer's disease
Issued Date
2024-04
Citation
Kim, Sujin. (2024-04). Korean red ginseng polysaccharide as a potential therapeutic agent targeting tau pathology in Alzheimer's disease. International Journal of Biological Macromolecules, 263. doi: 10.1016/j.ijbiomac.2024.130516
Type
Article
Author Keywords
Alzheimer&aposs diseaseTau pathologyRed ginseng polysaccharide
Keywords
NEURODEGENERATIONPHOSPHORYLATIONAGGREGATIONINVOLVEMENTGSK3-BETAPATHWAYNON-SAPONIN FRACTIONPANAX-GINSENGRICH POLYSACCHARIDEA-BETA
ISSN
0141-8130
Abstract
Tau is a microtubule-associated protein that plays a critical role in the stabilization and modulation of neuronal axons. Tau pathology is stronger associated with cognitive decline in patients with Alzheimer's disease (AD) than amyloid beta (Aβ) pathology. Hence, tau targeting is a promising approach for the treatment of AD. Previous studies have demonstrated that the non-saponin fraction with rich polysaccharide (NFP) from Korean red ginseng (KRG) can modulate tau aggregation and exert a therapeutic effect on AD. Therefore, we investigated the efficacy of NFP isolated from KRG on tau pathology in experimental models of AD. Our results showed that NFP from KRG ameliorated deposition and hyperphosphorylation of tau in the brain of 3xTg mice. Moreover, NFP from KRG modulated the aggregation and dissociation of tau K18 in vitro. We demonstrated the alleviatory effects of NFP from KRG on hyperphosphorylated tau and tau kinase in okadaic acid-treated HT22 cells. Furthermore, NFP from KRG mitigated Aβ deposition, neurodegeneration, and neuroinflammation in 3xTg mice. We revealed the neuroprotective effects of NFP from KRG on tau-induced neuronal loss in HT22 cells. Our results indicate that NFP extracted from KRG is a novel therapeutic agent for the treatment of AD associated with tau pathology. © 2024
URI
http://hdl.handle.net/20.500.11750/57023
DOI
10.1016/j.ijbiomac.2024.130516
Publisher
Elsevier
Show Full Item Record

File Downloads

  • There are no files associated with this item.

공유

qrcode
공유하기

Total Views & Downloads